Are Short Sellers On to Something at Navidea Biopharmaceuticals Inc (NAVB)? – Cardinal Health, Inc. (CAH)

Page 1 of 2

Since everyone loves a winner, it’s reasonable to assume that everyone hates a loser — everyone but short sellers, at least. These contrarian investors bet that hot stocks are primed to fall, aiming to turn their pessimism into profits.

Below, we take a look at biotech Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB), whose shares sold short, according to The Wall Street Journal, jumped 6%. That amounts to more than 17% of its float so its short interest ratio is 18 days to cover, or the number of days it would take to completely buy back all the shares sold short. The Motley Fool thinks seven days is a lot so it’s always possible we could see a short squeeze, but let’s see if the specialty pharma still has the power to make short work of short sellers.

Navidea Biopharmaceuticals snapshot

Market Cap $361 million
Revenues (TTM) >$1 million
1-Year Stock Return 4.7%
Estimated 5-Year EPS Growth N/A
Return on Investment (164.8%)
Dividend and Yield N/A
Recent Price $3.15
Shares Short Feb. 15 19.3 million
Shares Short Jan. 31 18.2 million
% Change 6.2%
CAPS Rating **

Sources: wsj.com, FinViz.com. N/A = not available; Navidea does not pay a dividend.

Just because the shorts are piling in doesn’t mean you should, too. Such stocks could have serious problems that warrant their short interest, but they might also just be stricken by short-term troubles. Only Foolish due diligence will tell you for certain.

Cardinal Health, Inc.The short story
Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB)’s lead product is Lymphoseek, a marker used to determine the spread of certain solid-tumor cancers into the lymphatic system, which has the potential to be a top-tier targeted imaging agent for lymphatic mapping. Following the disappointment associated with receiving a complete response letter from the FDA last September, Navidea finally has a PDUFA date at the end of next month that should determine once and for all whether it has addressed the regulatory agency’s concerns.

Fortunately, those issues centered on its contract manufacturing partners and not the imaging agent’s efficacy or safety, so considering it also filed a marketing authorization application with the European EMA, there might be some sense behind investors feeling confident that it has.

If the FDA does give Lymphoseek its imprimatur, Navidea and its U.S. marketing partner, Cardinal Health, Inc. (NYSE:CAH), plan to hit the ground running. There’s a worldwide market opportunity approaching $450 million, depending on who’s doing the counting, with the U.S. representing almost half of it at $200 million. The EU is second with $70 million, according to Navidea, and the rest of the world comes in at $180 million.

Of course, Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB) won’t recognize all that revenue because that’s just the addressable market. It’s going to have to split the proceeds with Cardinal Health, Inc. (NYSE:CAH), which also has the responsibility for determining what price to sell the agent (analysts have pegged it at around $400 per treatment ). As they’re also entitled to half the U.S. sales, it’s going to be a much smaller number that ends up on Navidea’s top line. Short sellers may agree there’s an opportunity here, but it’s likely a far smaller one than longs are suggesting.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!